SCHEMBL5039244

SCHEMBL5039244

COc1ccc(-c2nc(-c3cc(C(=O)NCC4CCCCC4)c(C)n3Cc3ccco3)cs2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 4/20 0.46
ALDH1A1 P00352 7/20 0.43
CDC25A P30304 2/20 0.42
CDC25B P30305 2/20 0.42
CDC25C P30307 2/20 0.42
DUSP3 P51452 2/20 0.42
POLB P06746 2/20 0.42
LMNA P02545 6/20 0.41
MEN1 O00255 5/20 0.41
KMT2A Q03164 5/20 0.41
MAPT P10636 4/20 0.41
HTT P42858 2/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
TP53 P04637 4/20 0.40
GAA P10253 2/20 0.39
KDM4E B2RXH2 1/20 0.39
TSHR P16473 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5043921 0.90 KLKB1 (0.52) KLKB1ALDH1A1CDC25ACDC25BCDC25C
SCHEMBL5048619 0.89 ALDH1A1 (0.47) KLKB1ALDH1A1CDC25ACDC25BCDC25C
SCHEMBL5047596 0.88 KLKB1 (0.49) KLKB1ALDH1A1CDC25ACDC25BCDC25C
SCHEMBL5043820 0.86 KLKB1 (0.48) KLKB1ALDH1A1POLBLMNAMEN1
SCHEMBL5044250 0.86 MAPT (0.52) KLKB1ALDH1A1CDC25ACDC25BCDC25C
SCHEMBL5044887 0.86 KLKB1 (0.47) KLKB1ALDH1A1CDC25ACDC25BCDC25C
SCHEMBL5133778 0.85 ALDH1A1 (0.51) KLKB1ALDH1A1CDC25ACDC25BCDC25C
SCHEMBL5048727 0.85 ALDH1A1 (0.47) KLKB1ALDH1A1POLBLMNAMEN1
SCHEMBL5132199 0.85 MAPT (0.59) KLKB1ALDH1A1CDC25ACDC25BCDC25C
SCHEMBL5046920 0.85 KLKB1 (0.46) KLKB1ALDH1A1POLBLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
US-7135488-B2 Pyrrolyl-thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R KLKB1 3949/4885ALDH1A1 959/4885CDC25A 1091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.